Work

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.7507

Authors: Andrew M. Evens, Fangxin Hong, Thomas Matthew Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Lynne I. Wagner, Stephen Maxted Ansell, Adam Matthew Petrich, Julie E. Chang, Timothy E. O'Brien, Puneet S. Cheema, Terrence Cescon, Keren Sturtz, Brad S. Kahl

Institutions: Tufts Medical Center, Harvard University, Mayo Clinic, Stanford Medicine, Stanford University, BC Cancer Agency, Northwestern University, MetroHealth Medical Center, Case Western Reserve University, HealthEast Care System, Colorado Permanente Medical Group, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2484017263

Cites:

Cited by: 7

Related to: 10